Advent Technologies (ADN) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
17 Nov, 2025Executive summary
Focused on hydrogen fuel cell and MEA technology, with operations in the US and Greece after exiting Denmark and the Philippines due to bankruptcy of Advent Technologies A/S in July 2024.
Revenue primarily from fuel cell systems, MEAs, and related services, with ongoing grant funding and R&D partnerships.
Significant business developments include a €34.5M EU Innovation Fund grant for the RHyno Project and ongoing collaborations with Airbus and the US Department of Defense.
Financial highlights
Revenue for Q3 2025 was $62K, down 52% year-over-year; nine-month revenue was $293K, down 92% year-over-year.
Net income from continuing operations for Q3 2025 was $8.6M, compared to a $9.6M loss in Q3 2024; nine-month net income was $1.6M, compared to a $29.2M loss year-over-year.
Net loss from discontinued operations was $8.9M for Q3 2025 and $9.9M for the nine months ended September 30, 2025.
Cash and cash equivalents at September 30, 2025, were $0.5M, with a working capital deficit of $16.0M.
EBITDA for Q3 2025 was $(2.2)M, improved from $(7.8)M in Q3 2024.
Outlook and guidance
Management expresses substantial doubt about the ability to continue as a going concern due to recurring losses, negative working capital, and insufficient cash to fund operations for the next twelve months.
Plans to raise additional capital through equity or debt and reduce expenditures; delays or failure to secure funding could result in curtailment or termination of operations.
Latest events from Advent Technologies
- Shareholders will vote on director elections, auditor ratification, stock issuance, and incentive plan changes.ADN
Proxy Filing - Annual meeting to elect a director, ratify auditor, and address other business, all board-recommended.ADN
Proxy Filing - Seeks up to $52M equity funding amid losses and going concern risk, leveraging HT-PEM tech and partnerships.ADN
Registration Filing - All agenda items, including director elections and plan amendments, were approved by majority vote.ADN
AGM 2025 - Severe liquidity challenges, legal settlements, and a major EU grant defined the quarter.ADN
Q2 2025 - Severe liquidity challenges persist despite cost cuts and a major EU grant, with going concern risks looming.ADN
Q1 2025 - Revenue up 113% year-over-year, but severe liquidity risk and going concern doubts persist.ADN
Q4 2024 - Director and auditor ratified; other business matters not approved at the meeting.ADN
AGM 2024 - Q4 revenue and cash fell as cost cuts and partnerships drove a shift to licensing and MEA focus.ADN
Q4 2023